While immunotherapy has revolutionized care for metastatic urothelial cancer, it doesn’t work for everyone. Patients who progress with or fail immunotherapy will need subsequent therapy, and there is limited data to guide treatment selection. New data from late-stage clinical trials introduce emerging targeted agents with great promise in improving outcomes for these patients.
Don’t miss this interactive webinar where experts in bladder cancer and managed care will discuss:
- Current strategies for evidence-based treatment decision-making for heavily pretreated patients
- Biomarkers that may improve therapy selection
- The latest clinical evidence supporting novel agents for the treatment of metastatic urothelial cancer